Annual EBITDA
-$789.33 M
-$818.61 M-2795.52%
December 31, 2024
Summary
- As of February 22, 2025, EXAS annual EBITDA is -$789.33 million, with the most recent change of -$818.61 million (-2795.52%) on December 31, 2024.
- During the last 3 years, EXAS annual EBITDA has fallen by -$140.05 million (-21.57%).
- EXAS annual EBITDA is now -2795.52% below its all-time high of $29.28 million, reached on December 31, 2023.
Performance
EXAS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
N/A
December 31, 2024
Summary
- EXAS quarterly EBITDA is not available.
Performance
EXAS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM EBITDA
N/A
December 31, 2024
Summary
- EXAS TTM EBITDA is not available.
Performance
EXAS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
EXAS EBITDA Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -2795.5% | - | - |
3 y3 years | -21.6% | - | - |
5 y5 years | -127.2% | - | - |
EXAS EBITDA Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -2795.5% | at low | ||||
5 y | 5-year | -2795.5% | at low | ||||
alltime | all time | -2795.5% | at low |
Exact Sciences EBITDA History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2024 | -$789.33 M(-2795.5%) | - | - |
Sep 2024 | - | $25.62 M(-26.5%) | $24.28 M(-58.5%) |
Jun 2024 | - | $34.87 M(-174.9%) | $58.50 M(-2582.1%) |
Mar 2024 | - | -$46.54 M(-550.4%) | -$2.36 M(-114.0%) |
Dec 2023 | $29.28 M(-107.0%) | $10.33 M(-82.7%) | $16.82 M(-124.0%) |
Sep 2023 | - | $59.84 M(-330.2%) | -$69.99 M(-69.5%) |
Jun 2023 | - | -$25.99 M(-5.0%) | -$229.34 M(-27.1%) |
Mar 2023 | - | -$27.35 M(-64.2%) | -$314.79 M(-25.1%) |
Dec 2022 | -$421.11 M(-35.1%) | -$76.48 M(-23.1%) | -$420.14 M(-19.2%) |
Sep 2022 | - | -$99.52 M(-10.7%) | -$520.17 M(-4.0%) |
Jun 2022 | - | -$111.44 M(-16.0%) | -$542.02 M(-2.3%) |
Mar 2022 | - | -$132.70 M(-24.8%) | -$554.92 M(-14.5%) |
Dec 2021 | -$649.28 M(-0.7%) | -$176.51 M(+45.4%) | -$649.28 M(-23.5%) |
Sep 2021 | - | -$121.36 M(-2.4%) | -$848.33 M(-4.3%) |
Jun 2021 | - | -$124.34 M(-45.2%) | -$886.08 M(+12.7%) |
Mar 2021 | - | -$227.07 M(-39.5%) | -$786.21 M(+20.4%) |
Dec 2020 | -$653.88 M(+88.2%) | -$375.56 M(+136.0%) | -$652.89 M(+25.0%) |
Sep 2020 | - | -$159.11 M(+550.3%) | -$522.14 M(+37.0%) |
Jun 2020 | - | -$24.47 M(-73.9%) | -$381.16 M(+1.5%) |
Mar 2020 | - | -$93.75 M(-61.7%) | -$375.69 M(+8.1%) |
Dec 2019 | -$347.46 M(+195.8%) | -$244.81 M(+1250.3%) | -$347.46 M(+146.4%) |
Sep 2019 | - | -$18.13 M(-4.6%) | -$141.03 M(-6.8%) |
Jun 2019 | - | -$19.00 M(-71.0%) | -$151.38 M(-2.4%) |
Mar 2019 | - | -$65.53 M(+70.7%) | -$155.02 M(+32.0%) |
Dec 2018 | -$117.46 M(+18.9%) | -$38.38 M(+34.8%) | -$117.46 M(+21.9%) |
Sep 2018 | - | -$28.47 M(+25.8%) | -$96.34 M(+6.1%) |
Jun 2018 | - | -$22.64 M(-19.0%) | -$90.84 M(-4.6%) |
Mar 2018 | - | -$27.96 M(+61.9%) | -$95.19 M(-3.7%) |
Dec 2017 | -$98.82 M(-36.4%) | -$17.27 M(-24.8%) | -$98.82 M(-14.5%) |
Sep 2017 | - | -$22.97 M(-14.9%) | -$115.55 M(-9.3%) |
Jun 2017 | - | -$26.99 M(-14.6%) | -$127.33 M(-10.5%) |
Mar 2017 | - | -$31.60 M(-7.1%) | -$142.21 M(-8.6%) |
Dec 2016 | -$155.49 M(+3.6%) | -$34.00 M(-2.2%) | -$155.53 M(-1.8%) |
Sep 2016 | - | -$34.75 M(-17.0%) | -$158.36 M(-3.9%) |
Jun 2016 | - | -$41.87 M(-6.8%) | -$164.78 M(+2.7%) |
Mar 2016 | - | -$44.91 M(+21.9%) | -$160.52 M(+7.1%) |
Dec 2015 | -$150.05 M(+55.9%) | -$36.83 M(-10.6%) | -$149.82 M(+4.4%) |
Sep 2015 | - | -$41.17 M(+9.5%) | -$143.56 M(+7.4%) |
Jun 2015 | - | -$37.60 M(+9.9%) | -$133.66 M(+16.3%) |
Mar 2015 | - | -$34.22 M(+11.9%) | -$114.91 M(+19.5%) |
Dec 2014 | -$96.23 M(+113.9%) | -$30.57 M(-2.2%) | -$96.14 M(+24.5%) |
Sep 2014 | - | -$31.27 M(+65.9%) | -$77.21 M(+36.0%) |
Jun 2014 | - | -$18.85 M(+22.0%) | -$56.77 M(+13.9%) |
Mar 2014 | - | -$15.45 M(+32.7%) | -$49.85 M(+11.1%) |
Dec 2013 | -$44.98 M(-12.5%) | -$11.64 M(+7.5%) | -$44.88 M(-4.3%) |
Sep 2013 | - | -$10.83 M(-9.3%) | -$46.87 M(-3.7%) |
Jun 2013 | - | -$11.94 M(+14.0%) | -$48.69 M(-5.2%) |
Mar 2013 | - | -$10.47 M(-23.2%) | -$51.38 M(+0.2%) |
Dec 2012 | -$51.40 M | -$13.63 M(+7.8%) | -$51.30 M(+8.6%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2012 | - | -$12.64 M(-13.5%) | -$47.24 M(+11.6%) |
Jun 2012 | - | -$14.62 M(+40.7%) | -$42.32 M(+23.5%) |
Mar 2012 | - | -$10.39 M(+8.5%) | -$34.26 M(+21.5%) |
Dec 2011 | -$28.21 M(+150.1%) | -$9.58 M(+24.0%) | -$28.21 M(+27.8%) |
Sep 2011 | - | -$7.73 M(+17.7%) | -$22.07 M(+24.9%) |
Jun 2011 | - | -$6.56 M(+51.4%) | -$17.67 M(+30.6%) |
Mar 2011 | - | -$4.33 M(+26.0%) | -$13.54 M(+20.0%) |
Dec 2010 | -$11.28 M(+24.3%) | -$3.44 M(+3.2%) | -$11.28 M(+16.8%) |
Sep 2010 | - | -$3.33 M(+37.4%) | -$9.65 M(+30.8%) |
Jun 2010 | - | -$2.43 M(+17.0%) | -$7.38 M(-0.0%) |
Mar 2010 | - | -$2.08 M(+14.1%) | -$7.38 M(-18.7%) |
Dec 2009 | -$9.07 M(+3.8%) | -$1.82 M(+71.9%) | -$9.07 M(-1.0%) |
Sep 2009 | - | -$1.06 M(-56.4%) | -$9.17 M(-7.2%) |
Jun 2009 | - | -$2.43 M(-35.6%) | -$9.88 M(+4.3%) |
Mar 2009 | - | -$3.77 M(+96.8%) | -$9.48 M(+13.5%) |
Dec 2008 | -$8.74 M(-25.1%) | -$1.92 M(+8.1%) | -$8.35 M(-18.7%) |
Sep 2008 | - | -$1.77 M(-12.4%) | -$10.28 M(+5.3%) |
Jun 2008 | - | -$2.02 M(-23.5%) | -$9.77 M(-0.4%) |
Mar 2008 | - | -$2.64 M(-31.2%) | -$9.81 M(+5.3%) |
Dec 2007 | -$11.67 M(-13.5%) | -$3.84 M(+205.2%) | -$9.31 M(+23.8%) |
Sep 2007 | - | -$1.26 M(-39.0%) | -$7.52 M(-22.2%) |
Jun 2007 | - | -$2.06 M(-3.8%) | -$9.67 M(-13.4%) |
Mar 2007 | - | -$2.15 M(+4.5%) | -$11.16 M(-17.3%) |
Dec 2006 | -$13.50 M(-10.1%) | -$2.05 M(-39.7%) | -$13.50 M(-6.6%) |
Sep 2006 | - | -$3.40 M(-4.4%) | -$14.46 M(-1.2%) |
Jun 2006 | - | -$3.56 M(-20.6%) | -$14.63 M(-4.3%) |
Mar 2006 | - | -$4.48 M(+48.8%) | -$15.28 M(+1.8%) |
Dec 2005 | -$15.01 M(-21.8%) | -$3.01 M(-15.8%) | -$15.01 M(-10.4%) |
Sep 2005 | - | -$3.58 M(-15.0%) | -$16.75 M(-5.6%) |
Jun 2005 | - | -$4.21 M(+0.2%) | -$17.75 M(-1.3%) |
Mar 2005 | - | -$4.21 M(-11.6%) | -$17.99 M(-6.3%) |
Dec 2004 | -$19.20 M(-33.4%) | -$4.75 M(+3.8%) | -$19.20 M(-5.2%) |
Sep 2004 | - | -$4.58 M(+2.9%) | -$20.25 M(-10.5%) |
Jun 2004 | - | -$4.45 M(-17.7%) | -$22.64 M(-12.4%) |
Mar 2004 | - | -$5.41 M(-6.9%) | -$25.84 M(-8.7%) |
Dec 2003 | -$28.84 M(+0.5%) | -$5.81 M(-16.5%) | -$28.30 M(-0.9%) |
Sep 2003 | - | -$6.96 M(-9.0%) | -$28.56 M(-1.8%) |
Jun 2003 | - | -$7.66 M(-2.7%) | -$29.08 M(-0.2%) |
Mar 2003 | - | -$7.87 M(+29.6%) | -$29.15 M(+1.6%) |
Dec 2002 | -$28.69 M(+14.1%) | -$6.07 M(-18.8%) | -$28.69 M(-2.5%) |
Sep 2002 | - | -$7.48 M(-3.2%) | -$29.43 M(+5.2%) |
Jun 2002 | - | -$7.72 M(+4.2%) | -$27.98 M(+5.4%) |
Mar 2002 | - | -$7.41 M(+8.7%) | -$26.55 M(+5.7%) |
Dec 2001 | -$25.13 M(+158.0%) | -$6.82 M(+13.1%) | -$25.13 M(+37.2%) |
Sep 2001 | - | -$6.03 M(-4.3%) | -$18.32 M(+49.0%) |
Jun 2001 | - | -$6.30 M(+5.2%) | -$12.29 M(+105.2%) |
Mar 2001 | - | -$5.99 M | -$5.99 M |
Dec 2000 | -$9.74 M(+101.3%) | - | - |
Dec 1999 | -$4.84 M(+20.3%) | - | - |
Dec 1998 | -$4.02 M | - | - |
FAQ
- What is Exact Sciences annual EBITDA?
- What is the all time high annual EBITDA for Exact Sciences?
- What is Exact Sciences annual EBITDA year-on-year change?
- What is the all time high quarterly EBITDA for Exact Sciences?
- What is the all time high TTM EBITDA for Exact Sciences?
What is Exact Sciences annual EBITDA?
The current annual EBITDA of EXAS is -$789.33 M
What is the all time high annual EBITDA for Exact Sciences?
Exact Sciences all-time high annual EBITDA is $29.28 M
What is Exact Sciences annual EBITDA year-on-year change?
Over the past year, EXAS annual EBITDA has changed by -$818.61 M (-2795.52%)
What is the all time high quarterly EBITDA for Exact Sciences?
Exact Sciences all-time high quarterly EBITDA is $59.84 M
What is the all time high TTM EBITDA for Exact Sciences?
Exact Sciences all-time high TTM EBITDA is $58.50 M